RxDoctor Payments Data

David Mosch, DO

Family Medicine · Oviedo, FLNPI 1366483687

Payments from drug & device makers

$9,456in general payments, 2019–2025

Across 561 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • Pfizer$845
  • AbbVie$773
  • Merck$522
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$9,33999%
  • Education$1171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,456 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$275,592
Medicare patients
584
Services billed
3,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$56,440
JardianceEmpagliflozin27$32,219
EliquisApixaban18$29,294
MounjaroTirzepatide13$19,044
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,785
Testosterone Cypionate56$3,189
Testosterone13$2,551
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,386
Atorvastatin Calcium183$1,494
Pregabalin20$1,337
Metformin Hcl ErMetformin Hcl102$1,301
Levothyroxine Sodium101$1,262
Rosuvastatin Calcium109$1,178
Gabapentin47$1,126
Metoprolol Succinate64$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,111$56,44045 claims
Boehringer IngelheimJardiance$1,027$32,21927 claims
PfizerEliquis$845$29,29418 claims
Lilly USA, LLCMounjaro$475$19,04413 claims
GSKTrelegy Ellipta$514$9,78515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Oviedo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →